{"nctId":"NCT00528957","briefTitle":"Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children","startDateStruct":{"date":"2006-12-28","type":"ACTUAL"},"conditions":["HIV Infections"],"count":97,"armGroups":[{"label":"Tenofovir DF","type":"EXPERIMENTAL","interventionNames":["Drug: Tenofovir DF"]},{"label":"stavudine or zidovudine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Zidovudine","Drug: Stavudine"]}],"interventions":[{"name":"Tenofovir DF","otherNames":["VireadÂ®"]},{"name":"Zidovudine","otherNames":[]},{"name":"Stavudine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Major Inclusion Criteria:\n\n* Documented laboratory diagnosis of HIV-1 infection\n* Plasma HIV-1 RNA \\< 400 copies/mL\n* Currently on a stable stavudine or zidovudine -containing antiretroviral therapy regimen for at least 12 weeks\n* Naive to tenofovir DF\n\nKey Inclusion Criteria for the First 96-Week Extension\n\n* Completed 48 weeks of treatment in Arm 1 or Arm 2 of the study\n* \\<18 years of age (at the start of the extension)\n* Participants initially randomized to Arm 2 will be given the option to replace stavudine or zidovudine with tenofovir DF in the 96-week extension at the investigator's discretion, if the investigator determines that tenofovir DF is safe and beneficial for the participant.\n\nKey Inclusion Criteria for the Second and Third 96-Week Extension and Fourth Open-Ended Extension\n\n* Completed of treatment with study drug in the first extension phase\n* \\<18 years of age at the start of the extension. This inclusion criterion is not applicable in those regions where tenofovir DF is not commercially available for treatment of HIV-1 infection in adults.\n\nKey Exclusion Criteria:\n\n* Participants receiving ongoing therapy with any of the following\n* Nephrotoxic agents\n* Systemic chemotherapeutic agents\n* Systemic corticosteroids\n* Interleukin 2 (IL 2) and other immunomodulating agents\n* Investigational agents\n* Pregnant or lactating participants\n* Evidence of a gastrointestinal malabsorption syndrome or chronic nausea or vomiting which may confer an inability to receive an orally administered medication\n* Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance\n* Malignancy other than cutaneous Kaposi's sarcoma (KS) or basal cell carcinoma.\n* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic therapy within 15 days prior to screening\n* Prior history of significant renal disease (ie, nephrotic syndrome, renal dysgenesis, polycystic kidney disease, congenital nephrosis)\n* Prior history of significant bone disease (ie, osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, osteochondroses, multiple bone fractures)\n\nNote: Other protocol defined Inclusion/ Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"15 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48","description":"This is the percentage of participants with HIV-1 RNA \\< 400 copies/mL after 48 weeks of exposure to randomized study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"91.8","spread":null},{"groupId":"OG002","value":"85.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot)","description":"This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA \\< 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null},{"groupId":"OG001","value":"89.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 50 Copies/mL, Snapshot)","description":"This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"81.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96","description":"This is the percentage of participants with HIV-1 RNA \\< 400 copies/mL after 96 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":null},{"groupId":"OG001","value":"85.4","spread":null},{"groupId":"OG002","value":"83.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144","description":"This is the percentage of participants with HIV-1 RNA \\< 400 copies/mL after 144 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.7","spread":null},{"groupId":"OG001","value":"87.5","spread":null},{"groupId":"OG002","value":"80.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 192 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 400 copies/mL after 192 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"82.5","spread":null},{"groupId":"OG002","value":"77.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 240 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 400 copies/mL after 240 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"75.7","spread":null},{"groupId":"OG002","value":"73.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 288 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 400 copies/mL after 288 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.5","spread":null},{"groupId":"OG001","value":"67.6","spread":null},{"groupId":"OG002","value":"73.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 336 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 400 copies/mL after 336 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"95.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 384 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 400 copies/mL after 384 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 432 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 400 copies/mL after 432 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"85.7","spread":null},{"groupId":"OG002","value":"95.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 480 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 400 copies/mL after 480 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"90.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 528 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 400 copies/mL after 528 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 48 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 50 copies/mL after 48 weeks of exposure to randomized study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":null},{"groupId":"OG001","value":"85.7","spread":null},{"groupId":"OG002","value":"68.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 96 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 50 copies/mL after 96 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","spread":null},{"groupId":"OG001","value":"68.3","spread":null},{"groupId":"OG002","value":"72.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 144 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 50 copies/mL after 144 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":null},{"groupId":"OG001","value":"75.0","spread":null},{"groupId":"OG002","value":"69.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 192 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 50 copies/mL after 192 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.6","spread":null},{"groupId":"OG001","value":"75.0","spread":null},{"groupId":"OG002","value":"71.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 240 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 50 copies/mL after 240 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"73.0","spread":null},{"groupId":"OG002","value":"71.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 288 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 50 copies/mL after 288 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.5","spread":null},{"groupId":"OG001","value":"62.2","spread":null},{"groupId":"OG002","value":"70.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 336 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 50 copies/mL after 336 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","spread":null},{"groupId":"OG001","value":"90.5","spread":null},{"groupId":"OG002","value":"88.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 384 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 50 copies/mL after 384 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"92.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 432 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 50 copies/mL after 432 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"71.4","spread":null},{"groupId":"OG002","value":"90.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 480 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 50 copies/mL after 480 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"72.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 528 Weeks","description":"This is the percentage of participants with HIV-1 RNA \\< 50 copies/mL after 528 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at 48 Weeks","description":"This is the change from baseline in CD4 percentage after 48 weeks of exposure to randomized study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"4.49"},{"groupId":"OG001","value":"1.1","spread":"4.73"},{"groupId":"OG002","value":"0.6","spread":"3.85"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at 96 Weeks","description":"This is the change from baseline in CD4 percentage after 96 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"4.08"},{"groupId":"OG001","value":"-0.1","spread":"3.60"},{"groupId":"OG002","value":"0.6","spread":"3.88"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at 144 Weeks","description":"This is the change from baseline in CD4 percentage after 144 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"5.61"},{"groupId":"OG001","value":"-0.1","spread":"3.83"},{"groupId":"OG002","value":"0.3","spread":"4.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at 192 Weeks","description":"This is the change from baseline in CD4 percentage after 192 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"5.57"},{"groupId":"OG001","value":"0.6","spread":"3.69"},{"groupId":"OG002","value":"0.8","spread":"4.58"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at 240 Weeks","description":"This is the change from baseline in CD4 percentage after 240 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"5.98"},{"groupId":"OG001","value":"-0.9","spread":"4.13"},{"groupId":"OG002","value":"0.1","spread":"5.16"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at 288 Weeks","description":"This is the change from baseline in CD4 percentage after 288 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"6.30"},{"groupId":"OG001","value":"0.5","spread":"4.77"},{"groupId":"OG002","value":"1.3","spread":"5.58"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at 336 Weeks","description":"This is the change from baseline in CD4 percentage after 336 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"7.19"},{"groupId":"OG001","value":"0.8","spread":"4.01"},{"groupId":"OG002","value":"1.4","spread":"5.82"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at 384 Weeks","description":"This is the change from baseline in CD4 percentage after 384 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"7.80"},{"groupId":"OG001","value":"1.6","spread":"1.90"},{"groupId":"OG002","value":"0.9","spread":"6.37"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at 432 Weeks","description":"This is the change from baseline in CD4 percentage after 432 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"6.41"},{"groupId":"OG001","value":"2.9","spread":"3.53"},{"groupId":"OG002","value":"1.1","spread":"5.66"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at 480 Weeks","description":"This is the change from baseline in CD4 percentage after 480 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"7.15"},{"groupId":"OG001","value":"5.0","spread":"10.00"},{"groupId":"OG002","value":"2.9","spread":"7.51"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at 528 Weeks","description":"This is the change from baseline in CD4 percentage after 528 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"3.89"},{"groupId":"OG002","value":"4.5","spread":"3.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks","description":"This is the change from baseline in CD4 cell count after 48 weeks of exposure to randomized study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-97","spread":"416.4"},{"groupId":"OG001","value":"-11","spread":"280.2"},{"groupId":"OG002","value":"2","spread":"385.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks","description":"This is the change from baseline in CD4 cell count after 96 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-77","spread":"408.3"},{"groupId":"OG001","value":"-56","spread":"305.6"},{"groupId":"OG002","value":"-67","spread":"358.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks","description":"This is the change from baseline in CD4 cell count after 144 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-139","spread":"438.2"},{"groupId":"OG001","value":"-146","spread":"245.3"},{"groupId":"OG002","value":"-142","spread":"345.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at 192 Weeks","description":"This is the change from baseline in CD4 cell count after 192 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-304","spread":"529.0"},{"groupId":"OG001","value":"-177","spread":"288.5"},{"groupId":"OG002","value":"-233","spread":"413.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at 240 Weeks","description":"This is the change from baseline in CD4 cell count after 240 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-369","spread":"529.9"},{"groupId":"OG001","value":"-296","spread":"252.6"},{"groupId":"OG002","value":"-329","spread":"401.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at 288 Weeks","description":"This is the change from baseline in CD4 cell count after 288 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-346","spread":"507.5"},{"groupId":"OG001","value":"-256","spread":"292.5"},{"groupId":"OG002","value":"-302","spread":"414.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at 336 Weeks","description":"This is the change from baseline in CD4 cell count after 336 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-415","spread":"569.4"},{"groupId":"OG001","value":"-283","spread":"252.2"},{"groupId":"OG002","value":"-350","spread":"443.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at 384 Weeks","description":"This is the change from baseline in CD4 cell count after 384 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-620","spread":"635.6"},{"groupId":"OG001","value":"-305","spread":"238.2"},{"groupId":"OG002","value":"-512","spread":"548.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at 432 Weeks","description":"This is the change from baseline in CD4 cell count after 432 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-795","spread":"559.2"},{"groupId":"OG001","value":"-302","spread":"355.2"},{"groupId":"OG002","value":"-631","spread":"545.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at 480 Weeks","description":"This is the change from baseline in CD4 cell count after 480 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-923","spread":"755.4"},{"groupId":"OG001","value":"-448","spread":"469.9"},{"groupId":"OG002","value":"-813","spread":"712.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count (Cells/mm^3) at 528 Weeks","description":"This is the change from baseline in CD4 cell count after 528 weeks of exposure to TDF.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-710","spread":"447.0"},{"groupId":"OG002","value":"-710","spread":"447.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":48},"commonTop":["Viral upper respiratory tract infection","Cough","Otitis media","Diarrhoea","Gastroenteritis"]}}}